

Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India

Kaustuv Nayak^{a#}, Kamalvishnu Gottimukkala^{a#}, Sanjeev Kumara^{a#}, Elluri Seetharami Reddy^{a,b#}, Venkata Viswanadh Edara^{c,d,e}, Robert Kauffman^{c,d}, Katharine Floyd^{c,d,e}, Grace Mantus^{c,d}, Deepali Savargaonkar^f, Pawan Kumar Goel^g, Satyam Arora^h, Manju Rahiⁱ, Carl W Davis^{c,j}, Susanne Linderman^{c,d}, Jens Wrammert^{c,d}, Mehul S Suthar^{c,d,e}, Rafi Ahmed^{c,j}, Amit Sharma^{f,k}, Kaja Murali-Krishna^{a,c,d§}, Anmol Chande^{a§}

^a ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi, India.

^b Kasuma School of Biological Sciences, Indian Institute of Technology, New Delhi, India

^c Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.

^d Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.

^e Yerkes National Primate Research Center, Atlanta, GA 30329, USA.

^f ICMR-National Institute of Malaria Research, Dwarka, New Delhi, India.

^g Shaheed Hasan Khan Mewat Government Medical College, Nalhar, Mewat, Haryana, India

^h Department of Transfusion Medicine, Super Speciality Pediatric Hospital and Post Graduate Teaching Institute, Noida, UP, India.

ⁱ Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi, India.

^j Dept of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.

^k Structural Parasitology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi, India.

Equal contributors / first authors

§ Equal corresponding authors

Keywords:

SARS-CoV-2, COVID-19, Receptor Binding Domain, Neutralizing antibodies, Memory B cells, India.

Running title:

Humoral and B cell memory in COVID-19 recovered individuals from India

Address for correspondence

Kaja Murali-Krishna,
Dept of Pediatrics, 2015 Upper gate Drive, Emory University School of Medicine, Emory University,
Atlanta, GA 30322, USA.
Murali.kaja@emory.edu

Anmol Chande,
ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology,
Aruna Asaf Ali Marg, New Delhi, India.
chandeanmol@gmail.com

Abstract

India is one of the countries most affected by the recent COVID-19 pandemic. Characterization of humoral responses to SARS-CoV-2 infection, including immunoglobulin isotype usage, neutralizing activity and memory B cell generation, is necessary to provide critical insights on the formation of immune memory in Indian subjects. In this study, we evaluated SARS-CoV-2 receptor-binding domain (RBD)-specific IgG, IgM, and IgA antibody responses, neutralization of live virus, and RBD-specific memory B cell responses in pre-pandemic healthy versus convalescent COVID-19 individuals from India. We observed substantial heterogeneity in the formation of humoral and B cell memory post COVID-19 recovery. While a vast majority (38/42, 90.47%) of COVID-19 recovered individuals developed SARS-CoV-2 RBD-specific IgG responses, only half of them had appreciable neutralizing antibody titers. RBD-specific IgG titers correlated with these neutralizing antibody titers as well as with RBD-specific memory B cell frequencies. In contrast, IgG titers measured against SARS-CoV-2 whole virus preparation, which includes responses to additional viral proteins besides RBD, did not show robust correlation. Our results suggest that assessing RBD-specific IgG titers can serve as a surrogate assay to determine the neutralizing antibody response. These observations have timely implications for identifying potential plasma therapy donors based on RBD-specific IgG in resource-limited settings where routine performance of neutralization assays remains a challenge.

Importance

Our study provides an understanding of SARS-CoV-2-specific neutralizing antibodies, binding antibodies and memory B cells in COVID-19 convalescent subjects from India. Our study highlights that PCR-confirmed convalescent COVID-19 individuals develop SARS-CoV-2 RBD-specific IgG antibodies, which correlate strongly with their neutralizing antibody titers. RBD-specific IgG titers, thus, can serve as a valuable surrogate measurement for neutralizing antibody responses. These findings have timely significance for selection of appropriate individuals as donors for plasma intervention strategies, as well as determining vaccine efficacy.

Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, emerged as a grave public health threat beginning in December 2019(1), paralyzing daily lives and causing economic downturns in many parts of the world. Currently, India is one of the countries most affected with more than 3 million COVID-19 confirmed cases and 60,000 associated deaths (2).

Intense efforts are underway to develop vaccines and antiviral therapeutics (3-11). These efforts require a detailed understanding of immune correlates of protection, formation of immune memory, and durability of these responses. Additionally, infusion of plasma derived from COVID-19 recovered individuals is also being explored as a treatment strategy (12-20). All these efforts require a detailed understanding of humoral immunity, immunoglobulin isotype usage and neutralizing activity following recovery from SARS-CoV-2 infection. Moreover, given that many of the SARS-CoV-2 neutralizing epitopes are located in the viral receptor binding domain (RBD) of the Spike (S) protein (21-29), it is important to evaluate the relationship between RBD-specific IgG titers and neutralizing antibody responses.

In this study, we evaluated IgG, IgA, IgM, neutralizing antibodies and memory B cell responses in PCR-confirmed COVID-19 convalescent subjects. Our results show that while a vast majority (38/42, 90.47%) of COVID-19 recovered individuals developed SARS-CoV-2 RBD-specific IgG responses, we were able to detect appreciable levels of neutralizing antibody responses in only half of the convalescent subjects. Neutralizing responses

correlated closely with RBD-specific IgG titers, but weakly with IgG titers measured against crude virus concentrate using a commercial ELISA kit. Taken together, these findings suggest that despite significant inter-individual variation in the RBD-specific IgG titers and neutralizing antibodies, RBD-specific IgG titers can serve as a valuable and robust surrogate measurement for neutralizing antibody responses. These observations not only provide a glimpse of humoral immune responses in COVID-19 recovered individuals from India, but also have timely implications for identifying potential plasma therapy donors using on RBD-specific IgG ELISA's in India where routine performance of neutralization assays remains a challenge.

Methods

Subject recruitment

COVID-19 recovered individuals were recruited at Shaheed Hasan Khan Mewati Government Medical College, Nuh, Haryana, India, Super Specialty Pediatric Hospital and Post Graduate Teaching Institute, Noida and ICMR-National Institute of Malaria Research, New Delhi. The Institutional ethical boards approved the study. Informed consent was obtained prior to inclusion in the study. All subjects (mean age 39.4 years, range 15 – 70 years) were SARS-CoV-2 PCR positive at the time of initial diagnosis, and were PCR negative when recruited for this study at 3.6 – 12 weeks post initial diagnosis (**Table 1**). Samples collected from healthy adult blood bank donors in the year 2018 are included as pre-pandemic controls.

SARS-CoV-2 specific PCR

SARS-CoV-2 specific rRT-PCR was performed as per the Indian government guidelines for COVID-19 diagnosis. Nasopharyngeal and throat swabs were collected in viral transport medium (VTM) (HiMedia, #AL 167)) and transported to the testing laboratory maintaining cold chain. All the samples were subjected to the first line screening assay or the ‘e’ gene assay as per the guidelines (30). Samples reactive by the first line assay were subjected to the RdRp gene assay (Invitrogen SuperScript™ III Platinum® One-Step Quantitative Kit (Cat. No.11732088)). Samples reactive for both the genes were labeled positive, while samples reactive to ‘e’ gene only were considered indeterminate and were subjected to repeat sampling. The same protocol was used to verify that the subjects were PCR negative at the time of recruitment for this study.

SARS-CoV-2 RBD-specific direct ELISA

Recombinant SARS-CoV-2 RBD gene was cloned, expressed, purified and standard direct ELISAs were performed as previously described (31). Briefly, purified RBD was coated on MaxiSorp plates (Thermo Fisher, #439454) at a concentration of 1 ug/mL in 100 uL phosphate-buffered saline (PBS) at 4°C overnight. The plates were washed extensively with PBS containing 0.05% Tween-20. Three-fold serially diluted plasma samples were added to the plates and incubated at room temperature for 1hr. After incubation, the plates were washed and the SARS-CoV-2 RBD specific IgG, IgM, IgA signals were detected by incubating with horseradish peroxidase (HRP) conjugated - anti-human IgG (Jackson ImmunoResearch Labs, #109-036-098), IgM (Jackson ImmunoResearch Labs, #109-036-129), or IgA (Jackson ImmunoResearch Labs, #109-036-011). Plates were then washed thoroughly and developed with o-phenylenediamine (OPD) substrate (Sigma, #P8787) in 0.05M phosphate-citrate buffer (Sigma, #P4809) pH 5.0, containing with 0.012% hydrogen peroxide (Fisher Scientific, #18755) just before use. Absorbance was measured at 490 nm.

Enumeration of SARS-CoV-2 RBD-specific memory B cells

Purified RBD protein (100 ug) was labeled with Alexa Fluor 488 using microscale protein labeling kit (Life Technologies, #A30006) as per manufacturer's protocol. PBMC's were stained with RBD-Alexa Fluor 488 for 1 hour at 4°C, followed by washing with PBS containing 0.25% FBS, and incubation with efluor780 Fixable Viability (Live Dead) dye (Life Technologies, #65-0865-14) and anti-human CD3, CD19, CD27, CD38 and IgD antibodies (BD Biosciences) for 30 minutes. Cells were washed twice with FACS buffer and acquired on BD LSR Fortessa X20. Data was analyzed using FlowJo software 10. SARS-CoV-2 RBD-specific

memory B cells were identified in cells positive for CD19, CD20, CD27 that were negative for IgD and CD3.

IgG ELISA for SARS-CoV-2 whole virus preparation

SARS-CoV-2 antigen specific IgG was detected using a commercially available assay (COVID-Kavach ELISA tests kit, Zydus diagnostics), which measures responses to antigen concentrated from gamma-irradiated SARS-CoV-2-infected tissue culture fluid as per the manufacturer's instructions (32, 33).

SARS-CoV-2 neutralization assay

Neutralization titers to SARS-CoV-2 were determined as previously described (31). Briefly infectious clone of the full-length mNeonGreen SARS-CoV-2 (2019-nCoV/USA_WA1/2020) was used to test heat-inactivated COVID-19 convalescent samples and healthy donor samples (pre-pandemic). Heat-inactivated serum was serially diluted three-fold in duplicate starting at a 1:20 dilution in a 96-well round-bottom plate and incubated between 750 FFU of ic-SARS-CoV-2-mNG for 1 h at 37°C. This antibody-virus mixture was transferred into the wells of a 96-well plate that had been seeded with Vero-E6 cells the previous day at a concentration of 2.5×10^4 cells/well. After 1 hour, the antibody-virus inoculum was removed and 0.85% methylcellulose in 2% FBS containing DMEM was overlaid onto the cell monolayer. Cells were incubated at 37°C for 24 hours. Cells were washed three times with 1XPBS (Corning Cellgro) and fixed with 125 µl of 2% paraformaldehyde in PBS (Electron Microscopy Sciences) for 30 minutes. Following fixation, plates were washed twice with 1x PBS and imaged on an ELISPOT reader (CTL Analyzer). Foci were counted using Viridot (34)

(counted first under the “green light” setting followed by background subtraction under the “red light” setting). FRNT-mNG₅₀ titers were calculated by non-linear regression analysis using the 4PL sigmoidal dose curve equation on Prism 8 (Graphpad Software). Neutralization titers were calculated as 100% x [1 - (average foci in duplicate wells incubated with the specimen) ÷ (average number of foci in the duplicate wells incubated at the highest dilution of the respective specimen)].

Statistical analysis

Statistical analysis was performed using GraphPad prism 8.0 software. Non-parametric t test (Mann-Whitney) was used to calculate the differences between groups. Non-parametric Spearman’s correlation coefficient (r) was used to calculate correlation between groups. A *p* value of ≤0.05 was considered as significant.

Results

SARS-CoV-2 RBD-specific humoral immunity in COVID-19 recovered individuals.

The demographic profile of COVID-19 recovered individuals recruited for this study is shown in **Table 1**. All subjects were at least 3.6 weeks past their initial SARS-CoV-2 positive diagnosis. RBD-specific ELISA curves for IgG, IgA and IgM at different dilutions of plasma in pre-pandemic healthy versus COVID-19 recovered individuals are shown in **Figure 1**. RBD-specific responses were highly elevated in COVID-19 recovered individuals as compared to pre-pandemic healthy controls (**Figure 1A,B,C, left versus middle panels**). Titers of IgG, IgA and IgM in the COVID-19 recovered individuals showed substantial inter-individual variation (**Figure 1 A, B, C, right panel**) - with IgG endpoint titers ranging from below detection to 24484 (2000 ± 619); IgA titers from below detection to 5686 (386 ± 136) and IgM titers from below detection to 2958 (515 ± 90). Four individuals had undetectable RBD-specific IgG and IgA titers. One of these individuals was also below detection for IgM (**Table 2**). Inter-individual heterogeneity was not related to the age of the individuals (**Figure 2A**) or the number of days that elapsed between PCR confirmation of infection and sample collection (**Figure 2B**).

SARS-CoV-2 specific neutralizing titers in COVID-19 recovered individuals.

To assess plasma neutralizing titers from COVID-19 convalescent individuals, we performed a live virus neutralization assay using a focus-reduction neutralization mNeonGreen (FRNT-mNG) assay (31). The neutralizing activity at different dilutions of plasma for pre-pandemic

healthy individuals (**Figure 3A**) and COVID-19 recovered individuals is shown in (**Figure 3B**). **Figure 3C** shows FRNT-mNG₅₀ titers calculated based on the plasma dilution that neutralized 50% of the virus. While all pre-pandemic healthy individuals had undetectable FRNT-mNG₅₀ titers, only half of the COVID-19 recovered individuals showed 50% or more neutralization even at a 1:20 dilution of plasma. Similar to RBD-specific IgG titers, the FRNT-mNG₅₀ titers were heterogeneous with the latter reaching titers as high as 682 (**Figure 3C**).

Previous studies in other viral infections have shown that all three antibody isotypes (IgG, IgA and IgM) can potentially neutralize (35-39). We next determined if any correlation exists between SARS-CoV-2 neutralizing titers and RBD-specific IgG, IgA, IgM binding antibody titers. We observed a positive correlation ($r=0.83$; $p<0.001$) between SARS-CoV-2 neutralizing titers and RBD-specific IgG titers (**Figure 4, left graph**) but not with IgA (**Figure 4, middle graph**) or IgM titers (**Figure 4, right graph**).

Plasma infusion therapy has recently been started in India as an intervention therapy for COVID-19. For this, plasma donors are being typically identified by the presence of IgG to SARS-CoV-2 by commercial ELISA tests (40). One of these tests detects IgG towards viral antigens concentrated from gamma-irradiated SARS-CoV-2-infected tissue culture fluid (32, 33). It was therefore of interest to examine the correlation between neutralization titers and IgG responses measured using this test. We observed that, of the 42 COVID-19 recovered individuals tested, 33 were IgG positive whereas 9 were below the assay cut off (**Figure 5A**). Of the 9 individuals that were below cut off, 4 also tested negative by the RBD-specific IgG ELISA (**Table 2**). All of the samples from the pre-pandemic healthy individuals were below

the limit of detection using both the ELISA methods. Most importantly, the IgG values obtained by whole virus-based ELISA did not show as robust a correlation ($r=0.56$) with neutralizing antibody titers (**Figure 5B**) as compared to those observed with RBD-specific IgG titers ($r=0.83$) (**Figure 4, left graph**).

Characterization of RBD-specific memory B cells in COVID-19 recovered individuals.

While circulating neutralizing antibodies help prevent re-infection by viruses, memory B cells allow for rapid production of new antibodies in case of re-infection. To address whether the COVID-19 recovered individuals generated memory B cells, we enumerated RBD-specific memory B cells using fluorescently-conjugated RBD antigen. An example of the flow cytometric gating strategy and RBD staining among the gated memory B cells is shown in **Figure 6A and 6B**. **Figure 6C** shows the frequency of RBD-specific memory B cells in a subset of the individuals where sufficient PBMCs were available. Though we found that there was substantial inter-individual variation in the frequency of SARS-CoV-2 RBD-specific memory B cells, their frequencies modestly correlated with RBD-specific IgG titers.

Discussion

Our study provides a detailed understanding of humoral immunity and memory B cells in COVID-19 recovered individuals from India. We examined SARS-CoV-2 neutralizing antibodies, IgG, IgM, IgA and memory B cells in pre-pandemic healthy versus COVID-19 recovered individuals and further evaluated inter-individual variation and relation among these.

Our correlative analysis of RBD-specific IgG binding titers with neutralizing antibody titers and memory B cells has important implications for not only identifying potential donors for plasma therapy but also for understanding humoral and cellular memory post COVID-19. Though current plasma therapy guidelines in India do not consider neutralizing antibody titers, United States Food and Drug Administration (FDA) guidelines recommend, when available, a neutralizing titer of 1:160 or 1:80 to be used for identifying potential plasma donors (41). Our correlation analysis shows that RBD-specific titers of more than 3668 can provide a suitable surrogate for identifying the individuals with neutralizing titers of above 1:160 and RBD-specific IgG titers 1926 for neutralizing titers of 1:80. Though larger scale studies are needed to establish robustness, these observations have timely implications to identify potential plasma therapy donors.

Our study raises important questions on formation of protective immune memory after recovering from COVID-19. We found that nearly half of the COVID-19 recovered individuals did not induce 50% neutralizing titers even at 1:20 dilution of plasma. This raises the

question of whether these individuals with low neutralizing antibodies also differ in formation of cellular immune memory. Our data show that individuals with low neutralizing antibodies indeed had lower memory B cells. Given that T cells may also contribute to COVID-19 protection, studies are needed to understand whether these individuals may also differ in the generation of memory CD8 and CD4 T cells (42-44).

The reason why only half of the COVID-19 recovered individuals developed appreciable levels of neutralizing antibody titers requires further investigation. This may be related to inter-individual differences in human immune responses associated with the expected heterogeneity in initial viral inoculum(45), initial viral loads (46-48), incubation period (49), host genetic factors (50-52) and disease severity (53, 54). This is consistent with previous studies that show relatively higher neutralizing antibodies in COVID-19 hospitalized patients during the acute febrile phase, or in recovered individuals that were previously hospitalized with severe COVID-19 disease (53, 54). It is noteworthy that the COVID-19 recovered individuals from our study had mild to moderate symptoms during the initial diagnosis. In light of these studies, our findings warrant future studies to seek an understanding of whether the individuals that have generated low or no neutralizing antibodies, IgG titers or memory B cells past recovery will be protected if they were re-exposed to SARS-CoV-2 or a related virus.

Acknowledgements

This research was supported in part by Indian Council of Medical Research VIR/COVID-19/02/2020/ECD-1 (A.C, K.M). K.N, E.S.R. are supported through Dengue Translational Research Consortia BIRAC/NBM-PMU/EST-TRC_ICGEB/2018 (A.C.); K.G. is supported through DBT grant BT/PR30260/MED/15/194/2018 (A.C, K.M); S.K. is supported through DBT/Wellcome Trust India Alliance Early Career Fellowship grant IA/E/18/1/504307. We are thankful to Mr. Satendra Singh and Mr. Ajay Singh, ICGEB, New Delhi for technical support; Director, SSPH & PGTI, Noida and Director, SHKM Government Medical College, Nuh, Haryana for facilitating the study. Vineet Menachery and Pei-Yong Shi for providing the icSARS-CoV-2mNG for the neutralization assays.

Author Contributions

Experimental work, data acquisition and analysis of data by K.N, K.G, S.K, E.S.R, V.V.E., K.F, R.K, S.L. C.D, J.W, M.S.S, and D.S. Clinical site coordination by D.S, P.K.G, S.A, A.S and M.R. Conceptualization and implementation by A.S, R.A, K.M, A.C. Manuscript writing by A.C and K.M. All authors contributed reviewing and editing the manuscript.

Figure legends

Figure 1: Evaluation of SARS-CoV-2 RBD specific IgG, IgA and IgM antibody responses.

(A) RBD-specific IgG, **(B)**, RBD-specific IgA; **(C)**, RBD-specific IgM. Left, pre-pandemic healthy (n=22), middle COVID-19 recovered (n=42); right, endpoint titers. ELISA cutoff values are calculated using the average plus 3 standard deviations of the 22 healthy controls at 1:100 dilution (shown as a dotted line). The unpaired analysis was done using non-

parametric Mann-Whitney-U test. $p \leq 0.05$ was considered significant. Assay cutoff value is marked with dotted line.

Figure 2. Correlation of age and day post initial diagnosis of COVID-19 recovered individuals with SARS-CoV-2 IgG, IgM and IgA titers.

(A). Age versus IgG (left, n=42), IgA (middle, n=42) or IgM (right, n=42) titers. **(B).** Time post initial diagnosis versus IgG (left, n=42), IgA (middle, n=42) or IgM (right, n=42) titers. Correlations were calculated by Spearman's correlation coefficient r . $p \leq 0.05$ is considered significant. Note that none of the data sets above reached significant values of correlation.

Figure 3. Evaluation of SARS-CoV-2 neutralizing antibodies in COVID-19 recovered individuals.

SARS-CoV-2 neutralizing activity at indicated dilutions of plasma is shown in pre-pandemic healthy (n=22, in grey) **(A)** and in COVID-19 recovered individuals (n=42, in blue) **(B)**. Dotted line represents the plasma dilution that leads to 50% neutralization. **(C)** Scatter plot shows neutralization titers (FRNT-mNG₅₀) in pre-pandemic healthy (n=22) and COVID-19 recovered (n=42) individuals. The unpaired analysis was done using non-parametric Mann-Whitney-U test. $p \leq 0.05$ was considered significant. Limit of detection is marked with a dotted line.

Figure 4. Correlation analysis of SARS-CoV-2-specific antibody responses versus neutralization titers.

Correlation analysis shows FRNT-mNG₅₀ titers (x-axis) versus RBD-specific IgG (Left), IgA (middle) and IgM (right) titers on y-axis in COVID-19 recovered individuals (n=42, blue dots). Correlation analysis was performed by log transformation of the endpoint ELISA titers followed by linear regression analysis. Correlations were calculated by Spearman's correlation coefficient r . $p \leq 0.05$ was considered significant. Dotted line on x-axis and y-axis indicate limit of detection.

Figure 5. Correlation analysis of SARS-CoV-2 whole virus specific IgG versus neutralizing titers.

(A). Scatter plots shows SARS-CoV-2 whole virus specific IgG measured using measured using commercial kit (Zydus diagnosis, Covid Kavach) in pre-pandemic healthy (n=5) and COVID-19 recovered (n=42). The unpaired analysis was done using non-parametric Mann-Whitney-U test. $p \leq 0.05$ was considered significant. **(B).** Correlation analysis of SARS-CoV-2 whole virus antigen specific IgG ELISA kit values (y-axis) versus neutralizing titers (x-axis) in COVID-19 recovered individuals (n=42). Correlations were calculated by Spearman's correlation coefficient r . $p \leq 0.05$ was considered significant. Dotted line on x-axis indicate limit of detection and on y-axis assay cut off.

Figure 6. SARS-CoV-2 RBD-specific memory B cell analysis in COVID-19 recovered individuals.

(A) Gating strategy used to identify memory B cells. **(B)** SARS-CoV-2 RBD-specific memory B cells on gated total memory B cells that were CD19 positive, CD20 high, IgD negative and CD27 high is shown. **(C)** Frequency of RBD-specific memory B cells of the total memory B cells in the COVID-19 recovered individuals (n= 13). **(D)** Correlation analysis shows frequency of RBD-specific memory B cells (x-axis) and the RBD-specific IgG titers (y-axis) in COVID-19 recovered individuals.

References:

1. WHO. 2020. Timeline: WHO's COVID-19 response.
2. Ministry of Health and Family Welfare GoI. 2020. COVID-19 INDIA as on: 26 August 2020.
3. Al-Kassmy J, Pedersen J, Kobinger G. 2020. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? *Viruses* 12.
4. Amanat F, Krammer F. 2020. SARS-CoV-2 Vaccines: Status Report. *Immunity* 52:583-589.
5. Dagotto G, Yu J, Barouch DH. 2020. Approaches and Challenges in SARS-CoV-2 Vaccine Development. *Cell Host Microbe* doi:10.1016/j.chom.2020.08.002.
6. Hashemian SM, Farhadi T, Velayati AA. 2020. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19. *Drug Des Devel Ther* 14:3215-3222.
7. Li Q, Kang C. 2020. Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. *Microorganisms* 8.
8. Malik S, Gupta A, Zhong X, Rasmussen TP, Manautou JE, Bahal R. 2020. Emerging Therapeutic Modalities against COVID-19. *Pharmaceuticals (Basel)* 13.
9. Nabil A, Uto K, Elshemy MM, Soliman R, Hassan AA, Ebara M, Shiha G. 2020. Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020. *EXCLI J* 19:992-1016.
10. Parvathaneni V, Gupta V. 2020. Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. *Life Sci* doi:10.1016/j.lfs.2020.118275:118275.
11. Verma HK, Merchant N, Verma MK, Kuru CI, Singh AN, Ulucan F, Verma P, Bhattacharya A, Bhaskar L. 2020. Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19). *Biomed J* doi:10.1016/j.bj.2020.07.008.
12. Bloch EM. 2020. Convalescent plasma to treat COVID-19. *Blood* 136:654-655.
13. Dhanasekaran S, Vajravelu LK, Venkatesalu V. 2020. Risk-benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19. *Postgrad Med J* doi:10.1136/postgradmedj-2020-138056.
14. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. 2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A* 117:9490-9496.
15. Focosi D, Anderson AO, Tang JW, Tuccori M. 2020. Convalescent Plasma Therapy for COVID-19: State of the Art. *Clin Microbiol Rev* 33.
16. Rabelo-da-Ponte FD, Silvello D, Scherer JN, Ayala AR, Klamt F. 2020. Convalescent Plasma Therapy on Patients with Severe or Life-Threatening COVID-19: A Metadata Analysis. *J Infect Dis* doi:10.1093/infdis/jiaa509.
17. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Eagar TN, Yi X, Zhao P, Rogers J, Shehabeldin A, Joseph D, Leveque C, Olsen RJ, Bernard DW, Gollihar J, Musser JM. 2020. Treatment of COVID-19 Patients with Convalescent

- 421 Plasma Reveals a Signal of Significantly Decreased Mortality. *Am J Pathol*
422 doi:10.1016/j.ajpath.2020.08.001.
- 423 18. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao
424 H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y,
425 Liu D, Zhang Z, Liu Y, Liu L. 2020. Treatment of 5 Critically Ill Patients With COVID-19
426 With Convalescent Plasma. *JAMA* doi:10.1001/jama.2020.4783.
- 427 19. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T. 2020. Treatment with
428 convalescent plasma for COVID-19 patients in Wuhan, China. *J Med Virol*
429 doi:10.1002/jmv.25882.
- 430 20. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X,
431 Zou Y, Zhang S. 2020. Treatment With Convalescent Plasma for Critically Ill Patients
432 With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Chest* 158:e9-e13.
- 433 21. Barnes CO, West AP, Jr., Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR,
434 Koranda N, Gristick HB, Gaebler C, Muecksch F, Lorenzi JCC, Finkin S, Hagglof T,
435 Hurley A, Millard KG, Weisblum Y, Schmidt F, Hatziioannou T, Bieniasz PD, Caskey M,
436 Robbiani DF, Nussenzweig MC, Bjorkman PJ. 2020. Structures of Human Antibodies
437 Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of
438 Antibodies. *Cell* 182:828-842 e16.
- 439 22. Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. 2007. Disappearance of antibodies
440 to SARS-associated coronavirus after recovery. *N Engl J Med* 357:1162-3.
- 441 23. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. 2020.
442 Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2
443 receptor. *Nature* 581:215-220.
- 444 24. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo
445 XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin
446 MT, Sheng Z, Huang Y, Shapiro L, Ho DD. 2020. Potent neutralizing antibodies against
447 multiple epitopes on SARS-CoV-2 spike. *Nature* 584:450-456.
- 448 25. Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, Verma V. 2020. COVID-19
449 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-
450 CoV-2. *PLoS Pathog* 16:e1008762.
- 451 26. Peterhoff D, Gluck V, Vogel M, Schuster P, Schutz A, Neubert P, Albert V, Frisch S,
452 Kiessling M, Pervan P, Werner M, Ritter N, Babl L, Deichner M, Hanses F, Lubnow M,
453 Muller T, Lunz D, Hitzentbichler F, Audebert F, Hahnel V, Offner R, Muller M, Schmid S,
454 Burkhardt R, Gluck T, Koller M, Niller HH, Graf B, Salzberger B, Wenzel JJ, Jantsch J,
455 Gessner A, Schmidt B, Wagner R. 2020. A highly specific and sensitive serological
456 assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with
457 neutralization. *Infection* doi:10.1007/s15010-020-01503-7.
- 458 27. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, Wang Q,
459 Zhou H, Yan J, Qi J. 2020. Structural and Functional Basis of SARS-CoV-2 Entry by
460 Using Human ACE2. *Cell* 181:894-904 e9.
- 461 28. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Reidy JX, Trivette A, Nargi RS, Sutton
462 RE, Suryadevara N, Williamson LE, Chen EC, Jones T, Day S, Myers L, Hassan AO, Kafai
463 NM, Winkler ES, Fox JM, Steinhardt JJ, Ren K, Loo YM, Kallewaard NL, Martinez DR,
464 Schafer A, Gralinski LE, Baric RS, Thackray LB, Diamond MS, Carnahan RH, Crowe JE.
465 2020. Potently neutralizing human antibodies that block SARS-CoV-2 receptor
466 binding and protect animals. *bioRxiv* doi:10.1101/2020.05.22.111005.

29. Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Chen EC, Binshtein E, Shrihari S, Ostrowski M, Chu HY, Didier JE, MacRenaris KW, Jones T, Day S, Myers L, Eun-Hyung Lee F, Nguyen DC, Sanz I, Martinez DR, Rothlauf PW, Bloyet LM, Whelan SPJ, Baric RS, Thackray LB, Diamond MS, Carnahan RH, Crowe JE, Jr. 2020. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. *Nat Med* doi:10.1038/s41591-020-0998-x.
30. ICMR-NIV. 2020. Standard Operating Procedure For Detection of 2019 novel coronavirus (2019-nCoV) in suspected human cases by rRT-PCR : confirmation assay.
31. Suthar MS, Zimmerman M, Kauffman R, Mantus G, Linderman S, Vanderheiden A, Nyhoff L, Davis C, Adekunle S, Affer M, Sherman M, Reynolds S, Verkerke H, Alter DN, Guarner J, Bryksin J, Horwath M, Arthur C, Saakadze N, Smith GH, Edupuganti S, Scherer EM, Hellmeister K, Cheng A, Morales JA, Neish AS, Stowell SR, Frank F, Ortlund E, Anderson E, Menachery V, Roupheal N, Metha A, Stephens DS, Ahmed R, Roback J, Wrammert J. 2020. Rapid generation of neutralizing antibody responses in COVID-19 patients. *medRxiv* doi:10.1101/2020.05.03.20084442.
32. Chaudhuri S TR, Kshetrapal P, Batra G, Shrivastava T, Desiraju KB, Kang G, Bhatnagar S. 2020. Comparative Evaluation of SARS-CoV-2 IgG Assays in India. *medRxiv preprint* doi:https://doi.org/10.1101/2020.08.12.20173856.
33. Sapkal G, Shete-Aich A, Jain R, Yadav PD, Sarkale P, Lakra R, Baradkar S, Deshpande GR, Mali D, Tilekar BN, Majumdar T, Kaushal H, Gurav Y, Gupta N, Mohandas S, Deshpande K, Kaduskar O, Salve M, Patil S, Gaikwad S, Sugunan AP, Ashok M, Giri S, Shastri J, Abraham P, Gangakhedkar RR, Covid Support Team: Pawar S PSSVNMVMBJASPMRKRSDK. 2020. Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG. *Indian J Med Res* 151:444-449.
34. Katzelnick LC, Coello Escoto A, McElvany BD, Chavez C, Salje H, Luo W, Rodriguez-Barraquer I, Jarman R, Durbin AP, Diehl SA, Smith DJ, Whitehead SS, Cummings DAT. 2018. Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. *PLoS Negl Trop Dis* 12:e0006862.
35. Chua CL, Sam IC, Chiam CW, Chan YF. 2017. The neutralizing role of IgM during early Chikungunya virus infection. *PLoS One* 12:e0171989.
36. Ejemel M, Li Q, Hou S, Schiller ZA, Tree JA, Wallace A, Amcheslavsky A, Kurt Yilmaz N, Buttigieg KR, Elmore MJ, Godwin K, Coombes N, Toomey JR, Schneider R, Ramchetty AS, Close BJ, Chen DY, Conway HL, Saeed M, Ganesa C, Carroll MW, Cavacini LA, Klempner MS, Schiffer CA, Wang Y. 2020. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. *Nat Commun* 11:4198.
37. Lizeng Q, Nilsson C, Sourial S, Andersson S, Larsen O, Aaby P, Ehn Lund M, Bjorling E. 2004. Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals. *J Virol* 78:7016-22.
38. Skountzou I, Satyabhama L, Stavropoulou A, Ashraf Z, Esser ES, Vassilieva E, Koutsouanos D, Compans R, Jacob J. 2014. Influenza virus-specific neutralizing IgM antibodies persist for a lifetime. *Clin Vaccine Immunol* 21:1481-9.
39. Sterlin D MA, Miyara M, Mohr A, Anna F, Claer L, Quentric P, Fadlallah J, Ghillani P, Gunn C, Hockett R, Mudumba S, Guihot A, Luyt CE, Mayaux J, Beurton A, Fourati S,

- 513 Lacorte JM, Yssel H, Parizot C, Dorgham K, Charneau P, Amoura Z, Gorochoff G. 2020.
- 514 IgA dominates the early neutralizing antibody response to SARS-CoV-2. medRxiv
- 515 doi:<https://doi.org/10.1101/2020.06.10.20126532>.
- 516 40. cdsco.gov.in. 2020. A Phase II, Open Label, Randomized Controlled Trial to Assess the
- 517 Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated
- 518 Complications in Moderate Disease.
- 519 41. FDA. 2020. Recommendations for Investigational COVID-19 Convalescent Plasma.
- 520 42. Chen Z, John Wherry E. 2020. T cell responses in patients with COVID-19. Nat Rev
- 521 Immunol 20:529-536.
- 522 43. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA,
- 523 Sutherland A, Premkumar L, Jardi RS, Marrama D, de Silva AM, Frazier A, Carlin AF,
- 524 Greenbaum JA, Peters B, Krammer F, Smith DM, Crotty S, Sette A. 2020. Targets of T
- 525 Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
- 526 Unexposed Individuals. Cell 181:1489-1501 e15.
- 527 44. Jesenak M, Brndiarova M, Urbancikova I, Rennerova Z, Vojtkova J, Bobcakova A, Ostro
- 528 R, Banovcin P. 2020. Immune Parameters and COVID-19 Infection - Associations With
- 529 Clinical Severity and Disease Prognosis. Front Cell Infect Microbiol 10:364.
- 530 45. Welten SPM, Redeker A, Toes REM, Arens R. 2016. Viral Persistence Induces Antibody
- 531 Inflation without Altering Antibody Avidity. J Virol 90:4402-4411.
- 532 46. Akondy RS, Johnson PL, Nakaya HI, Edupuganti S, Mulligan MJ, Lawson B, Miller JD,
- 533 Pulendran B, Antia R, Ahmed R. 2015. Initial viral load determines the magnitude of
- 534 the human CD8 T cell response to yellow fever vaccination. Proc Natl Acad Sci U S A
- 535 112:3050-5.
- 536 47. Arankalle VA, Lole KS, Arya RP, Tripathy AS, Ramdasi AY, Chadha MS, Sangle SA,
- 537 Kadam DB. 2010. Role of host immune response and viral load in the differential
- 538 outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients. PLoS
- 539 One 5.
- 540 48. Reddy V, Mani RS, Desai A, Ravi V. 2014. Correlation of plasma viral loads and
- 541 presence of Chikungunya IgM antibodies with cytokine/chemokine levels during
- 542 acute Chikungunya virus infection. J Med Virol 86:1393-401.
- 543 49. Hermesh T, Moltedo B, Lopez CB, Moran TM. 2010. Buying time-the immune system
- 544 determinants of the incubation period to respiratory viruses. Viruses 2:2541-58.
- 545 50. Carter-Timofte ME, Jorgensen SE, Freytag MR, Thomsen MM, Brinck Andersen NS, Al-
- 546 Mousawi A, Hait AS, Mogensen TH. 2020. Deciphering the Role of Host Genetics in
- 547 Susceptibility to Severe COVID-19. Front Immunol 11:1606.
- 548 51. Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, Sharifi N, Erzurum S, Eng C,
- 549 Cheng F. 2020. New insights into genetic susceptibility of COVID-19: an ACE2 and
- 550 TMPRSS2 polymorphism analysis. BMC Med 18:216.
- 551 52. LoPresti M, Beck DB, Duggal P, Cummings DAT, Solomon BD. 2020. The Role of Host
- 552 Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic
- 553 Review of Human Literature. Am J Hum Genet doi:10.1016/j.ajhg.2020.08.007.
- 554 53. Kong WH, Zhao R, Zhou JB, Wang F, Kong DG, Sun JB, Ruan QF, Liu MQ. 2020. Serologic
- 555 Response to SARS-CoV-2 in COVID-19 Patients with Different Severity. Virol Sin
- 556 doi:10.1007/s12250-020-00270-x.
- 557 54. Liu ZL, Liu Y, Wan LG, Xiang TX, Le AP, Liu P, Peiris M, Poon LLM, Zhang W. 2020.
- 558 Antibody Profiles in Mild and Severe Cases of COVID-19. Clin Chem 66:1102-1104.

Table 1. COVID-19 recovered individuals characteristics (n=42)*

Age in years	Mean (Range)	39.4 (15-70)
Males/Females		38/4
Days post PCR diagnosis	Mean (Range)	47.3 (25-84)

*COVID-19 recovered individuals were recruited at Shaheed Hasan Khan Mewati Government Medical College, Nuh, Haryana, India. Super Speciality Paediatric Hospital and Post Graduate Teaching Institute, Noida and ICMR-National Institute of Malaria Research, New Delhi. All subjects were SARS-CoV-2 PCR positive at the time of initial diagnosis and were PCR negative when recruited for this study at 4.8 – 11 weeks post initial diagnosis.

Table 2. Individual characteristics of the COVID-19 recovered subjects

Subject number	Age	Gender (Male,M Female,F)	Days Post PCR Diagnosis	SARS CoV-2 RBD specific Immunoglobulin titers*			SARS Cov-2 whole Virus specific IgG ELISA values**	Neutralization titer (FRNT-mNG ₅₀)***
				IgG	IgM	IgA		
1	23	M	84	2220	565	220	26	39
2	22	F	84	354	283	<100	3	26
3	68	M	40	464	<100	<100	19	<20
4	35	M	51	4547	393	545	6	113
5	50	M	37	1354	301	275	7	81
6	29	M	34	<100	866	<100	<1.5	<20
7	27	M	34	422	104	450	<1.5	<20
8	25	M	34	222	1031	<100	26	<20
9	21	M	40	650	588	153	9	25
10	39	M	38	612	539	5686	12	23
11	46	M	38	2011	325	224	24	55
12	31	M	38	494	828	183	10	<20
13	20	M	41	944	274	<100	14	49
14	36	M	41	228	279	1614	<1.5	<20
15	34	M	44	282	302	<100	4	<20
16	70	M	44	1250	220	518	14	43
17	40	M	45	464	112	101	16	<20
18	32	M	41	867	381	399	<1.5	<20
19	57	M	45	1069	354	231	<1.5	<20
20	27	F	49	1935	528	<100	23	80
21	36	M	49	3156	355	593	28	166
22	24	M	45	<100	387	<100	<1.5	<20
23	55	F	45	<100	778	<100	<1.5	<20
24	15	M	45	212	496	<100	<1.5	<20
25	49	M	45	4183	2958	397	17	657
26	26	M	48	2352	<100	<100	16	48
27	54	F	54	1202	<100	182	15	49
28	53	M	52	799	197	417	12	<20
29	52	M	48	2611	249	157	23	46
30	45	M	62	1490	401	<100	15	50
31	52	M	56	10127	421	437	21	434
32	26	M	47	<100	<100	<100	<1.5	<20
33	32	M	57	701	177	<100	14	<20
34	44	M	49	815	428	<100	20	<20
35	32	M	40	829	140	<100	6	29
36	44	M	42	4685	494	295	26	167
37	22	M	77	3954	764	690	24	209
38	49	M	25	24484	2828	459	22	682
39	55	M	51	371	753	<100	17	<20
40	36	M	51	621	350	104	17	<20
41	60	M	51	156	459	<100	17	34
42	62	M	47	467	354	<100	6	<20

*ELISA end point titre limit of detection is 100.

**ELISA was performed with a commercial kit (Covid Kavach, Zydus) using 1:100 dilution of plasma as per by the manufacturer's recommendation. Assay cut off is 1.5.

***Neutralization titres: Neutralization assay were performed using 3 fold dilution of plasma, starting at 1:20 up to 1:43740. Limit of detection for FRNT-mNG₅₀ is 20.

560
561
562
563




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6